Short interest for Apellis Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Apellis Pharmaceuticals's stock. Short interest data is updated every two weeks.

Apellis Pharmaceuticals Stock (NASDAQ:APLS), Short Interest Report

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

News

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

APLS

AXON

ICUI

STRL

TARS

TREE

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Pre-Market Outlook

ABBV

PINS

SKYW

Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday

Penny Stocks

DAVA

NFLX

PLUG

VRTX

Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals Inc

<p>In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715191212_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Apellis Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$49.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Apellis Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Apellis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Apellis Pharmaceuticals</h2>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<h3>Apellis Pharmaceuticals: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Apellis Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>545.89%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-60.51%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-41.51%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Apellis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-11.02%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Apellis Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.57</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals

<p>UBS  analyst Eliana Merle   maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $89 to $85.</p>


UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

<p>Needham  analyst Joseph Stringer   reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $85 price target.</p>


Reiteration

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

WIIM

Apellis Pharmaceuticals shares are trading lower following Q1 earnings.

<p>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.52) by 3.85 percent. This is a 65.38 percent increase over losses of $(1.56) per share from the same period last year.  The company reported quarterly sales of $172.32 million which beat the analyst consensus estimate of $163.35 million by 5.49 percent.  This is a 284.26 percent increase over sales of $44.85 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Apellis Pharmaceuticals Q1 EPS $(0.54) Misses $(0.53) Estimate, Sales $172.32M Beat $163.35M Estimate

<p>Financial giants have made a conspicuous bearish move on Apellis Pharmaceuticals. Our analysis of options history for Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) revealed 15 unusual trades.</p>
<p>Delving into the details, we found 40% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $496,047, and 6 were calls, valued at $511,853.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $75.0 for Apellis Pharmaceuticals, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Apellis Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Apellis Pharmaceuticals's significant trades, within a strike price range of $40.0 to $75.0, over the past month.</p>
<h3>Apellis Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714493780_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$7.8</td>
<td>$5.0</td>
<td>$6.5</td>
<td>$45.00</td>
<td>$162.5K</td>
<td style="text-align: right;">0</td>
<td>6.7K</td>
</tr>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.35</td>
<td>$1.3</td>
<td>$2.3</td>
<td>$45.00</td>
<td>$106.5K</td>
<td style="text-align: right;">254</td>
<td>1.5K</td>
</tr>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.7</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$45.00</td>
<td>$90.0K</td>
<td style="text-align: right;">254</td>
<td>500</td>
</tr>
<tr>
<td>APLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$40.00</td>
<td>$84.8K</td>
<td style="text-align: right;">107</td>
<td>147</td>
</tr>
<tr>
<td>APLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$9.1</td>
<td>$8.1</td>
<td>$8.7</td>
<td>$50.00</td>
<td>$78.3K</td>
<td style="text-align: right;">334</td>
<td>16</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apellis Pharmaceuticals</h3>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<p>Having examined the options trading patterns of Apellis Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Apellis Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 4,136,096, the price of APLS is down -8.19% at $43.92. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 7 days.</li>
</ul>
<h3>Expert Opinions on Apellis Pharmaceuticals</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $74.2.</p>
<ul>
<li>In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $85. </li>
<li>An analyst from Mizuho has decided to maintain their Neutral rating on Apellis Pharmaceuticals, which currently sits at a price target of $52. </li>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $85. </li>
<li>In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $92. </li>
<li>An analyst from Wedbush has decided to maintain their Neutral rating on Apellis Pharmaceuticals, which currently sits at a price target of $57. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Apellis Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

A Closer Look at Apellis Pharmaceuticals's Options Market Dynamics

<p>Mizuho  analyst Graig Suvannavejh   maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $60 to $52.</p>


Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $52

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $92 price target.</p>


HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target

Apellis Pharmaceuticals shares are trading higher after the European Medicines Agency resets Pegcetacoplan review for geographic atrophy to day 180 of initial assessment.

Biotech

Health Care

General

European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Apellis Pharmaceuticals</strong>.</p>
<p>Looking at options history for Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 7% of the investors opened trades with bullish expectations and 92% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $90,630 and 11, calls, for a total amount of $1,684,106.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $75.0 for Apellis Pharmaceuticals over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Apellis Pharmaceuticals's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apellis Pharmaceuticals's whale activity within a strike price range from $40.0 to $75.0 in the last 30 days. </p>
<h3>Apellis Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713457903_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.3</td>
<td>$4.8</td>
<td>$5.1</td>
<td>$60.00</td>
<td>$604.8K</td>
<td>133</td>
<td>1</td>
</tr>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.6</td>
<td>$3.0</td>
<td>$3.3</td>
<td>$60.00</td>
<td>$404.1K</td>
<td>5</td>
<td>1.0K</td>
</tr>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.0</td>
<td>$2.75</td>
<td>$2.75</td>
<td>$70.00</td>
<td>$275.0K</td>
<td>1.0K</td>
<td>0</td>
</tr>
<tr>
<td>APLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$10.0</td>
<td>$8.9</td>
<td>$9.4</td>
<td>$40.00</td>
<td>$94.0K</td>
<td>199</td>
<td>100</td>
</tr>
<tr>
<td>APLS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.95</td>
<td>$2.9</td>
<td>$2.95</td>
<td>$45.00</td>
<td>$63.1K</td>
<td>1.3K</td>
<td>0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apellis Pharmaceuticals</h3>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<p>In light of the recent options history for Apellis Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Apellis Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 756,695, the price of APLS is down -1.04% at $47.53. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for Apellis Pharmaceuticals</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $73.5.</p>
<ul>
<li>Maintaining their stance, an analyst from Wedbush continues to hold a Neutral rating for Apellis Pharmaceuticals, targeting a price of $57. </li>
<li>Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $92.</li>
<li>Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Apellis Pharmaceuticals with a target price of $60. </li>
<li>In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $85. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apellis Pharmaceuticals options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Behind the Scenes of Apellis Pharmaceuticals's Latest Options Trends

<p>Wedbush  analyst Laura Chico   maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and lowers the price target from $67 to $57.</p>


Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57

<p>14 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.43, a high estimate of $92.00, and a low estimate of $60.00. Marking an increase of 13.47%, the current average surpasses the previous average price target of $70.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713189639_0_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Apellis Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Apellis Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Apellis Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Apellis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Apellis Pharmaceuticals</h2>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Apellis Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately <strong>545.89%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Apellis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-60.51%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Apellis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-41.51%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-11.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.57</strong>, Apellis Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Apellis Pharmaceuticals

<p>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) has outperformed the market over the past 5 years by 11.97% on an annualized basis producing an average annual return of 24.08%. Currently, Apellis Pharmaceuticals has a market capitalization of $6.65 billion. </p>
<p><strong>Buying $1000 In APLS:</strong> If an investor had bought $1000 of APLS stock 5 years ago, it would be worth <strong>$2,958.46</strong> today based on a price of $55.12 for APLS at the time of writing.</p>
<h3>Apellis Pharmaceuticals's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1712775622_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today

<p>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) has outperformed the market over the past 5 years by 10.69% on an annualized basis producing an average annual return of 23.52%. Currently, Apellis Pharmaceuticals has a market capitalization of $7.02 billion. </p>
<p><strong>Buying $1000 In APLS:</strong> If an investor had bought $1000 of APLS stock 5 years ago, it would be worth <strong>$3,017.45</strong> today based on a price of $58.20 for APLS at the time of writing.</p>
<h3>Apellis Pharmaceuticals's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711746019_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today

<p>Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Apellis Pharmaceuticals, revealing an average target of $79.4, a high estimate of $106.00, and a low estimate of $60.00. This current average reflects an increase of 18.51% from the previous average price target of $67.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711562488_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Apellis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$81.00</td>
<td>-</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$106.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Apellis Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Apellis Pharmaceuticals analyst ratings.</strong></a></p>
<h2>Discovering Apellis Pharmaceuticals: A Closer Look</h2>
<p>Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</p>
<h3>Understanding the Numbers: Apellis Pharmaceuticals's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Apellis Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>545.89%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-60.51%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Apellis Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-41.51%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-11.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Apellis Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <b>0.57</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals

<p>Mizuho  analyst Graig Suvannavejh   maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Neutral and maintains $60 price target.</p>


Mizuho Maintains Neutral on Apellis Pharmaceuticals, Maintains $60 Price Target

Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Apellis Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/apls-stock-quote/"><strong>APLS</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Apellis Pharmaceuticals reported earnings per share of -54 cents. This was below the analyst estimate for EPS of -52 cents.</li><li>The company reported revenue of $172.33 million.</li><li>This was 5.49% better than the analyst estimate for revenue of $163.35 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/apls-stock-earnings-apellis-pharmaceuticals-for-q1-of-2024/">APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Apellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript

Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Strin...

Buy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial Outlook

Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Apellis Pharmaceuticals (APLS – Research Report). The associ...

Strong Buy for Apellis Pharmaceuticals as Syfovre Dominates GA Market with Robust Sales and Growth Potential

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) and keeping the price target ...

Buy Rating Affirmed for Apellis Pharmaceuticals Amid Robust Sales and Market Expansion Potential

Yigal Nochomovitz, an analyst from Citi, maintained the Buy rating on Apellis Pharmaceuticals (APLS – Research Report). The associated price target...

Optimistic Outlook: Buy Rating on Apellis Pharmaceuticals Amid Strong Syfovre Sales and Upcoming VALIANT Trial Results

Wells Fargo analyst Derek Archila maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $57....

Apellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive Pressures

Apellis stock sell-off over Syfovre sales "overdone," says Citi

Press Releases

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

Legal

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Apellis Pharmaceuticals Stock (NASDAQ:APLS), Short Interest Report

People Also Watch